DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ceritinib
Ceritinib
Clinical Response of the Novel Activating ALK-I1171T
ZYKADIA (Ceritinib) RATIONALE for INCLUSION in PA PROGRAM
Clinical Response of the Novel Activating ALK-I1171T Mutation In
First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
ALK Tyrosine Kinase Inhibitors, 5.01.538
Zykadia (Ceritinib)
Systemic Therapy Update
Zykadia) for Metastatic Non-Small Cell Lung Cancer
Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
205755Orig1s000
Study Protocol & Schedule of Activities
Lung Cancer Agents – Unified Formulary
Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase
Dual Kinase Targeting in Leukemia
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Encephalic Leukocytoclastic Vasculitis During Treatment with Sunitinib for Renal Cell Carcinoma: a Case Report
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Top View
Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Pharmacology Update
Bladder Cancer
Drug-Drug Interactions of Common Chemotherapeutic Agents And
Open Full Page
Efficacy of Ceritinib After Alectinib for ALK-Positive Non-Small Cell Lung
Cancer Drug Indications with Orphan Designation by the FDA (2008 - 2017) and Comparison with the EMA
NCCN Non-Small Cell Lung Cancer V.1.2018 – Meeting – June 16, 2017
The Potent ALK Inhibitor Brigatinib (AP26113)
Ceritinib: Drug Information
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
Non–Small Cell Lung Cancer Erminia Massarelli and Vassiliki Papadimitrakopoulou
Expanding the Portfolio of Anti-ALK Weapons
205755Orig1s000